Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIS793 + mFOLFIRINOX in resectable pancreatic adenocarcinoma
NCT05546411Phase 2Terminated
- Start
- Jan 2023
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nisevokitug in pancreatic adenocarcinoma (PDAC) (2 arms). Primary endpoint: Major Pathological Response Rate. Started Jan 2023; status: terminated.
02
Drugs
nisevokitug
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05546411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546411.